TMO Stock Price Today (October 2026) — Thermo Fisher Scientific Inc. Analysis & Key Metrics 2026-10-07
Thermo Fisher Scientific Inc. (TMO) is trading at $662.06, up 0.83% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $652.85 (1.4% downside).
- Volatility is low (23.20% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.50% YoY) alongside competitive pressures in the Diagnostics & Research space.
TMO Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Thermo Fisher Scientific Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $283.28B
P/E Ratio
Forward P/E: 22.43
Revenue Growth
Year over Year
Analyst Target
-1.4% downside from target
Key Investor Questions About TMO
What investors need to know before buying
Based on current market data, TMO presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 54.75)
- Fundamentals say: Looking solid (debt and growth supportive)
TMO's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TMO investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $42.55B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, TMO stock traded between $435.27 and $683.63 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.20% annualized volatility and β=0.80, the stock exhibits low sensitivity to market moves—making TMO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Dodge and Cox’s Bullish Stance on Thermo Fisher Scientific (TMO)
Dodge & Cox Fund, an investment management company, released its second-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. You can download a copy of the letter here. U.S. equities achieved new all-time highs in Q2 2026, driven by a rally in the technology sector, led by memory semiconductor stocks. In Q2 2026, the […]
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
Thermo Fisher Scientific (TMO) Launches Gibco CHO K1 Panel On A Fair Value Question
Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day share price return of 5.81%, building on a strong 90-day share price return of 31.55% as launches like the Gibco CHO-K1 Catalog Panel feed into a broader pipeline story. Over a longer horizon, the 1-year...
Thermo Fisher Scientific (TMO) Rolls Out New Media Panel For Biologics Development
Thermo Fisher Scientific (NYSE:TMO) has introduced the Gibco CHO-K1 Catalog Panel, a new off the shelf media offering for biologics developers. The panel includes cGMP ready, chemically defined, animal origin free basal and feed media aimed at broad process development and manufacturing use. The new solution is designed to give biologics and biosimilars producers scalable, ready to use options for cell culture performance, productivity, and product quality. The launch of the Gibco CHO-K1...
3 Reasons to Sell TMO and 1 Stock to Buy Instead
Thermo Fisher’s 36.4% return over the past six months has outpaced the S&P 500 by 20.1%, and its stock price has climbed to $652.30 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Mayo Clinic, Thermo Fisher partner to create Precure
The company will generate population-scale molecular data to inform development of diagnostics, therapies and other healthcare products.
Jim Cramer Said These 2 Stocks Were Sold Because Of A Rotation – But Is He Right?
Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of […]
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time highs, though the energy sector declined. Continued earnings growth, especially among […]
Explore More Analysis for TMO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 21, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) is currently trading at $662.06. The RSI (14-day) is at 54.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $652.85 implies 1.4% downside from current levels. Volatility is moderate at 23.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Thermo Fisher Scientific Inc. (TMO): The trailing P/E ratio is 32.99, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 22.43, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.06, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 4.31. Price-to-Sales is 4.90. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering TMO, the consensus price target is $652.85. This represents a 1.4% downside from the current price of $662.06. The range spans from a low target of $520.00 to a high target of $780.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Thermo Fisher Scientific Inc. (TMO) pays a dividend with a current yield of approximately 0.28%. The annualized dividend rate is $1.80 per share. The payout ratio is 9.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 15, 2026.
Key risks for Thermo Fisher Scientific Inc. (TMO) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Thermo Fisher Scientific Inc.'s (TMO) current debt and financial health profile: Total debt stands at $42.55B. The debt-to-equity ratio is 0.81x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.55, indicating strong short-term liquidity. The quick ratio is 1.01. The company holds $4.06B in cash and equivalents. Free cash flow is positive at $6.24B, providing a cushion for debt servicing and shareholder returns.